Priority 11 from the Psoriasis PSP

Pottinger, 2018 This systematic review concluded that the potential effect of biologics on pregnancy outcomes specifically in women with psoriasis has not been adequately studied to quantify accurately. Data on use in other indications is limited. Women of child-bearing potential should be advised routinely to use regular contraception; however, when planning conception the risks and benefits of continuing vs. stopping therapy should be discussed on a case-by-case basis. To address the clinical uncertainty, large disease-matched cohort studies are required, taking into account potential confounders such as disease activity, concomitant therapies and maternal demographics. Psoriasis-specific pharmacovigilance registries, for example the British Association of Dermatologist Biologics Intervention Register (BADBIR) in collaboration with others via the European Psoriasis Registry Network (PSONET), provide opportunity to collate such data.